×
The Standard Group Plc is a multi-media organization with investments in media platforms spanning newspaper print operations, television, radio broadcasting, digital and online services. The Standard Group is recognized as a leading multi-media house in Kenya with a key influence in matters of national and international interest.
  • Standard Group Plc HQ Office,
  • The Standard Group Center,Mombasa Road.
  • P.O Box 30080-00100,Nairobi, Kenya.
  • Telephone number: 0203222111, 0719012111
  • Email: [email protected]

Africa not ready for vaccine, says WHO

Health & Science

The World Health Organisation has urged African countries to improve their capacity to vaccinate populations against Covid-19, warning that the continent is still “far from ready” for mass immunisation.

With three coronavirus vaccines now showing efficacy rates of at least 70 per cent, the UN body on Thursday called on Africa to “ramp up” preparations for “the continent’s largest ever immunisation drive”. The African region is so far only 33 per cent ready to roll out Covid-19 vaccines, the World Health Organisation (WHO) said in a statement.

That figure, based on data provided by 40 countries on a series of “readiness criteria”, is well below a desired 80 per cent benchmark. “Planning and preparation will make or break this unprecedented endeavour,” WHO Africa Director Matshidiso Moeti said during a virtual press briefing.

The main concerns are inadequate funding plans, monitoring tools and community outreach. “There are key logistical and financing gaps where international solidarity will be imperative,” Moeti said.

The WHO estimates that rolling out a Covid-19 vaccine to just priority populations in Africa will cost around $5.7 billion.

African countries will be partially subsidised by the COVAX global Covid-19 distribution scheme. The World Bank has also set aside $12 billion to help developing countries finance their immunisation programmes.

Mr Moeti said the aim was to vaccinate three per cent of Africa’s population by March 2021, and 20 per cent by the end of the year.

Other health experts at the briefing said additional research was needed to develop vaccines more suitable to the continent. 

They noted that a promising vaccine developed by Pfizer and BioNTech, which tested at a 95 per cent success rate at its latest trial, must be kept at -70 degrees celsius - all but impossible for most hospitals in Africa. “We really should be doing some of this vaccine research in the African region,” said Helen Rees, chair of the WHO’s Africa immunisation advisory group.

So far only Egypt, Morocco, Kenya and South Africa have active Covid-19 vaccine trials.

Moeti said it was important for the continent not to fall behind on global preparations for Covid-19 vaccinations even though coronavirus infections had somewhat plateaued. She noted that Africa has been relatively spared compared to the rest of the world, with over 2.1 million cases and 50,000 deaths recorded to date.

Related Topics


.

Trending Now

.

Popular this week